Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taletrectinib - AnHeart Therapeutics

Next Previous
Drug Profile

Taletrectinib - AnHeart Therapeutics

Alternative Names: AB-106; Dovbleron; DS-6051; DS-6051a; DS-6051b; IBI-344; Ibtrozi; Taletrectinib-adipate

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Inc
  • Developer AnHeart Therapeutics; Innovent Biologics
  • Class Amines; Antineoplastics; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Phenyl ethers; Pyridazines; Small molecules
  • Mechanism of Action ROS1 protein inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours

Most Recent Events

  • 11 Jun 2025 Registered for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (PO)
  • 11 Jun 2025 Updated efficacy data from the phase II TRUST I and TRUST II trial in Non-small cell lung cancer released by Nuvation Bio
  • 06 Mar 2025 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top